UNSPSC 51292804: Lysergide

This classification denotes a serotonin antagonist and serotonin agonist with the molecular formula C20H25N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8NA5SWF92O, chemically known as d-lysergic acid n,n-diethylamide but generally known as lysergide, which bears US NIH Compound Identifier 3981. European Medicines Agency schedules Lysergide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08628MIG.

UNSPSC 51292804 Lysergide is a Commodity code that does not align with recent state and local procurement activity. The three most recent opportunities posted under or near this code involve naloxone and drug-deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products—none of which fall within the scope of lysergide, a controlled pharmaceutical substance with severely restricted medical and research applications. The mismatch suggests either miscoding in the state and local procurement system or a cataloging error; the code shows little relevant recent activity in the state and local market.

Seminole County, Florida posted an IFB on June 30, 2026 (response due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug-deactivation systems annually. The Texas Health and Human Services Commission issued an RFI on April 3, 2026 regarding direct-to-manufacturer prescription programs for its pharmacy benefit system. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers for participating state and local facilities. None of these solicitations involve lysergide procurement, and the recurring involvement of state pharmacy benefit programs, cooperative purchasing vehicles, and county health agencies suggests that active pharmaceutical buying in the state and local market centers on naloxone, generics, and OTC products rather than specialized research or controlled substances.